.25 mg semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) and a shorter life Wegovy Pill: First Oral GLP-1

The reconstitution for these is simply consuming the capsule as provided

The STEP-1 extension trial showed that participants regained two-thirds of their lost weight within one year of stopping semaglutide [10]

Retrieved from Walsh, T

Weight management shouldnt be a solo act encouragement matters Progress in weight and wellness doesnt happen in isolation

J Neural Transm Suppl 72:3941 Hopp SC, Lin Y, Oakley D, Roe AD, DeVos SL, Hanlon D, Hyman BT (2018) The role of microglia in processing and spreading of bioactive tau seeds in Alzheimers disease

Over-loss and muscle pooled SURMOUNT-1 through -4 analysis found BMI below 22 in 7.26% of tirzepatide-treated participants